Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biohaven Relaunches As Biohaven Ltd. After Pfizer Buyout Closes

New launch — Relaunched Biohaven focuses on epilepsy, OCD and SMA • Source: Shutterstock

Related Content

Neurocrine Adds Epilepsy Assets From Xenon

Dec 02 2019

Biohaven’s Non-Migraine Portfolio Takes Another Hit As Verdiperstat Fails In ALS

Sep 29 2022

Biohaven’s Life Without CGRP Inhibitors Gets Off To A Rocky Start

May 23 2022

Pfizer To Put Big Marketing Muscle Behind Migraine With Biohaven Purchase

May 10 2022

Biohaven Returns To Well With Bristol License, Acquires Channel Biosciences

Feb 25 2022

Biohaven Faces Another Pipeline Upset, But Focus Remains On Migraine Portfolio

Sep 27 2021

Clene Sees Path Forward For ALS Candidate Despite Late-Stage Trial Failure

Oct 04 2022

Related Companies

Pfizer Inc.

Biohaven Pharmaceutical Holding Company Ltd.

Channel Biosciences, LLC

Xenon Pharmaceuticals, Inc.

UCB S.A.

Clene, Inc.

Sanofi

Alnylam Pharmaceuticals Inc.

Agios Pharmaceuticals, Inc.

Additional Topics

Business Strategies Companies M & A Commercial Neurology BioPharmaceutical

More from Strategy

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window